{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:04:05Z","timestamp":1790186645833,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The present study evaluated the effects of dapagliflozin, a SGLT2 inhibitor, or dapagliflozin plus metformin versus metformin monotherapy in patients with metabolic syndrome. This study included patients who admitted in Jiangxi Provincial People\u2019s Hospital from January 1, 2017 to December 31, 2019 and were diagnosed with metabolic syndrome. A total of 248 participants were randomly assigned to divide into three groups: dapagliflozin group; metformin group; dapagliflozin in combined with metformin group. Dapagliflozin group and metformin group were associated with similar improvements in components of metabolic syndrome. Relative to dapagliflozin or metformin monotherapy, dapagliflozin combined with metformin provided greater improvements in components of metabolic syndrome. So did HOMA-IR scores, fasting plasma insulin and inflammatory indicators (hsCRP, PMN\/HDL-C and Monocytes\/HDL-C). Dapagliflozin improved all components of metabolic syndrome in patients with metabolic syndrome. Furthermore, dapagliflozin combined with metformin showed more meaningful improvements in any of components of metabolic syndrome than dapagliflozin or metformin monotherapy.<\/jats:p>","DOI":"10.1038\/s41598-021-03773-z","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T11:13:41Z","timestamp":1639998821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome"],"prefix":"10.1038","volume":"11","author":[{"given":"Lan","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenfen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohe","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"issue":"9468","key":"3773_CR1","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","volume":"365","author":"RH Eckel","year":"2005","unstructured":"Eckel, R. H., Grundy, S. M. & Zimmet, P. Z. The metabolic syndrome. Lancet 365(9468), 1415\u20131428 (2005).","journal-title":"Lancet"},{"issue":"9468","key":"3773_CR2","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/S0140-6736(05)66375-1","volume":"365","author":"D Gu","year":"2005","unstructured":"Gu, D. et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365(9468), 1398\u20131405 (2005).","journal-title":"Lancet"},{"issue":"20","key":"3773_CR3","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1161\/CIRCULATIONAHA.105.539528","volume":"112","author":"PW Wilson","year":"2005","unstructured":"Wilson, P. W., D\u2019Agostino, R. B., Parise, H., Sullivan, L. & Meigs, J. B. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112(20), 3066\u20133072 (2005).","journal-title":"Circulation"},{"issue":"9710","key":"3773_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0140-6736(09)61794-3","volume":"375","author":"RH Eckel","year":"2010","unstructured":"Eckel, R. H., Alberti, K. G., Grundy, S. M. & Zimmet, P. Z. The metabolic syndrome. Lancet 375(9710), 181\u2013183 (2010).","journal-title":"Lancet"},{"issue":"42","key":"3773_CR5","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1093\/eurheartj\/ehw110","volume":"37","author":"N Marx","year":"2016","unstructured":"Marx, N. & McGuire, D. K. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur. Heart J. 37(42), 3192\u20133200 (2016).","journal-title":"Eur. Heart J."},{"issue":"4","key":"3773_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380(4), 347\u2013357 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"3773_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377(7), 644\u2013657 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"3773_CR8","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373(22), 2117\u20132128 (2015).","journal-title":"N. Engl. J. Med."},{"key":"3773_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/DMSO.S126291","volume":"10","author":"MJ Davies","year":"2017","unstructured":"Davies, M. J., Merton, K. W., Vijapurkar, U., Balis, D. A. & Desai, M. Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Metab. Syndr. Obes. 10, 47\u201355 (2017).","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"3","key":"3773_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.23736\/S0391-1977.16.02550-5","volume":"43","author":"M Gonz\u00e1lez-Ortiz","year":"2018","unstructured":"Gonz\u00e1lez-Ortiz, M., M\u00e9ndez-Del Villar, M., Mart\u00ednez-Abundis, E. & Ram\u00edrez-Rodr\u00edguez, A. M. Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Minerva Endocrinol. 43(3), 229\u2013235 (2018).","journal-title":"Minerva Endocrinol."},{"issue":"1","key":"3773_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0977-z","volume":"19","author":"A Fuchigami","year":"2020","unstructured":"Fuchigami, A. et al. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: A prospective, randomized study (DIVERSITY-CVR). Cardiovasc. Diabetol. 19(1), 1 (2020).","journal-title":"Cardiovasc. Diabetol."},{"issue":"8","key":"3773_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.7326\/0003-4819-142-8-200504190-00009","volume":"142","author":"TJ Orchard","year":"2005","unstructured":"Orchard, T. J. et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial. Ann. Intern. Med. 142(8), 611\u2013619 (2005).","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"3773_CR13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1742-1241.2012.02911.x","volume":"66","author":"RR Henry","year":"2012","unstructured":"Henry, R. R. et al. Dapagliflozin, metformin XR, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int. J. Clin. Pract. 66(5), 446\u2013456 (2012).","journal-title":"Int. J. Clin. Pract."},{"issue":"21","key":"3773_CR14","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.jacc.2007.01.088","volume":"49","author":"J Jeppesen","year":"2007","unstructured":"Jeppesen, J. et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: A population-based study. J. Am. Coll. Cardiol. 49(21), 2112\u20132119 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3773_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cca.2019.06.019","volume":"496","author":"P Reddy","year":"2019","unstructured":"Reddy, P., Lent-Schochet, D., Ramakrishnan, N., McLaughlin, M. & Jialal, I. Metabolic syndrome is an inflammatory disorder: A conspiracy between adipose tissue and phagocytes. Clin. Chim. Acta 496, 35\u201344 (2019).","journal-title":"Clin. Chim. Acta"},{"issue":"23","key":"3773_CR16","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1161\/01.CIR.0000132467.45278.59","volume":"109","author":"PM Ridker","year":"2004","unstructured":"Ridker, P. M., Wilson, P. W. & Grundy, S. M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk. Circulation 109(23), 2818\u20132825 (2004).","journal-title":"Circulation"},{"issue":"3","key":"3773_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/MOL.0b013e32832ac03e","volume":"20","author":"S Devaraj","year":"2009","unstructured":"Devaraj, S., Singh, U. & Jialal, I. Human C-reactive protein and the metabolic syndrome. Curr. Opin. Lipidol. 20(3), 182\u2013189 (2009).","journal-title":"Curr. Opin. Lipidol."},{"issue":"1","key":"3773_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1161\/01.CIR.102.1.42","volume":"102","author":"AD Festa","year":"2000","unstructured":"Festa, A. D. et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102(1), 42\u201347 (2000).","journal-title":"Circulation"},{"key":"3773_CR19","doi-asserted-by":"publisher","DOI":"10.1515\/hmbci-2019-0070","author":"I Jialal","year":"2020","unstructured":"Jialal, I., Jialal, G., Adams-Huet, B. & Ramakrishnan, N. Neutrophil and monocyte ratios to high-density lipoprotein-cholesterol and adiponectin as biomarkers of nascent metabolic syndrome. Horm. Mol. Biol. Clin. Investig. https:\/\/doi.org\/10.1515\/hmbci-2019-0070 (2020).","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"3773_CR20","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.2174\/1871530320999200831165116","volume":"21","author":"J Jiang","year":"2021","unstructured":"Jiang, J., Lin, L. & Chen, P. Comparison of dapaglifozin and liraglutide in patients with poorly controlled type 2 diabetes mellitus: A 24-week, open, double-centered, head to head trial. Endocr. Metab. Immune Disord. Drug Targets 21, 1366 (2021).","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"issue":"Suppl 2","key":"3773_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP.17.S2.1","volume":"17","author":"Y Handelsman","year":"2011","unstructured":"Handelsman, Y. et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr. Pract. 17(Suppl 2), 1\u201353 (2011).","journal-title":"Endocr. Pract."},{"issue":"Suppl 1","key":"3773_CR22","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jcjd.2013.01.010","volume":"37","author":"G Booth","year":"2013","unstructured":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Booth, G. & Cheng, A. Y. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Methods. Can. J. Diabetes 37(Suppl 1), S4\u2013S7 (2013).","journal-title":"Can. J. Diabetes"},{"issue":"Suppl 1","key":"3773_CR23","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jcjd.2013.01.009","volume":"37","author":"AY Chen","year":"2013","unstructured":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee & Chen, A. Y. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. Can. J. Diabetes 37(Suppl 1), S1\u2013S3 (2013).","journal-title":"Can. J. Diabetes"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03773-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03773-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03773-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T18:17:30Z","timestamp":1670091450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03773-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3773"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03773-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]},"assertion":[{"value":"26 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24263"}}